New Multiple Sclerosis Drug May Repair Nerve Demyelination
As researchers continue to develop a clearer understanding of the underlying causes of multiple sclerosis (MS), it is…
Articles by Patricia Silva, PhD
Consumption of High Amounts of Salt May Worsen MS Symptoms, Study Suggests
A diet high in salt can worsen multiple sclerosis (MS) symptoms, as well as increase the risks of neurological deterioration, according to…
Blind Cyclist Joins Bike to the Bay Sept. 20-21 to Raise Funds for Multiple Sclerosis
For many people such as attorney Richard Nenno from Delaware, joining a fundraising sport event stems from a highly…
Biogen’s Tysabri, Novartis’ Gilenya Being Considered For Funding In New Zealand Health System
The Pharmaceutical Management Agency (PHARMAC) is considering a funding proposal that includes five treatments for multiple sclerosis (MS), namely two…
90 Secondary Progressive MS Patients To Be Recruited To Test Novel Experimental Therapy
New Zealand and  Australian-based biotechnology company Innate Immunotherapeutics recently announced that it has begun to recruit patients…
Big Multiple Sclerosis Conference Scheduled For September in Boston
Just yesterday, the President of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Suhayl Dhib-Jalbut, publicly announced the…
Promising Multiple Sclerosis Research Partnership Between Biogen Idec, Regulus Renewed
Regulus Therapeutics, Inc., a San Diego-based biopharmaceutical company that specializes in the research and development of experimental drugs that…
NUC Reports Promising Results of Stem Cell Transplants in MS Patients
A new stem cell transplant therapy may offer patients with multiple sclerosis (MS) an alternative treatment option. According to a…
Italian Researchers Connect Fatigue in MS Patients To Localized Brain Damage
The common symptom of fatigue experienced by multiple sclerosis (MS) patients may be caused by regional damage in the…
UPDATE: Australian Authorities Warn About Unapproved MS Stem Cell Treatments After Death in Russia
Australian authorities are alerting Multiple Sclerosis patients to the risk of unproven stem cell treatments that are being performed…
After Delay, Innate Immunotherapeutics’ MIS416 Trial For Secondary Progressive MS Therapy To Begin Enrolling in August
In spite of an eight week delay, New Zealand-based Innate Immunotherapeutics is still planning to enroll patients for its phase 2b…
Biogen Idec’s Injection Plegridy Approved in Europe to Treat RRMS
The European Commission granted marketing authorization for the use of Plegridy, a drug developed by…
Complementary and Alternative Medicine is Gaining Credibility Among MS Patients
Complementary and alternative medicine (CAM) are no substitutes for the regular treatment of multiple sclerosis (MS), however, they are…
FDA Removes Partial Clinical Hold for CTP-354, Concert Pharmaceuticals’ Novel Drug for MS, Spasticity
The U.S. Food and Drug Administration (FDA) recently notified Concert Pharmaceuticals that the company had fulfilled all necessary preclinical…
USC PhD Student Creates Project to Treat MS with Nanotechnology
A Ph.D. student at the University of Southern California (USC) Viterbi Ming Hsieh Department of Electrical Engineering, Kun Yue, is…
NICE Turns Back and Approves Biogen’s Oral MS Drug Tecfidera in the UK
The UK’s National Institute for Health and Care Excellence (NICE) gave a positive final appraisal determination to the use…
8 Compounds Potentially Useful For Treating MS Discovered Using Innovative Research Tool
Eight new drugs that are able to stimulate the nervous system were discovered by a research team at UC San…
Startup ImStem Raising Funds For Novel Stem-Cell MS Treatment
Startup biotech company ImStem Biotechnology is looking to raise additional funding for their upcoming clinical…
Lemtrada For RRMS Still Under Review in the U.S., Now Approved in Scotland
The Scottish Medicines Consortium (SMC)  announced the approval of the drug Lemtrada, produced by Genzyme, for…
Music Professor With MS Featured In PBS Documentary About the Disease
The American Public Broadcasting Service (PBS) recently aired a documentary about a University of Central Oklahoma (UCO) music professor,…
Bike MS Ride in Colorado Raises $3.8 million To Support Research
Bike MS, a two-day ride between Westminster and Fort Collins, in Colorado, raised $3.8 million to support the multiple…
MS Care Costs Rose 60 Percent in 7 Years, According To Study
The main costs of care for multiple sclerosis (MS) patients continue to be driven predominantly by common MS “sequelae”…
MS Genzyme Drug Lemtrada Approved in Argentina, Still Under Review in US
Lemtrada, a drug produced by Genzyme for the treatment of adult patients suffering from relapsing remitting multiple…
Actavis Plans Generic Version of Acorda’s Multiple Sclerosis Drug Ampyra
Acorda Therapeutics recently announced receiving a notice letter from pharmaceutical company Actavis Plc indicating their plans to commercialize a generic version of Ampyra, Acorda’s…
Hilton Foundation Opens Submissions for Innovation Award in MS
The Conrad N. Hilton Foundation is accepting submissions for the first edition of the Marilyn Hilton Award for Innovation in Multiple…
Roche Turns to MS Research on Agreement with Versant Ventures
The Swiss pharmaceutical company Roche recently announced a partnership agreement with California-based Inception Sciences and venture capital firm Versant Ventures. The…
Compassionate Use Trial of Innate Immunotherapeutics’ Multiple Sclerosis Drug Shows Positive Results
Australian biotechnology company Innate Immunotherapeutics’ trial for a drug designed to treat secondary progressive multiple sclerosis (SPMS)…
Physiotherapist Creates Group Exercise Manual for MS Patients
Group exercise could be very beneficial in improving the health of multiple sclerosis patients, according to Sheila Lennon, Physiotherapy…
Multiple Sclerosis Foundation Launches First MS Online Radio Station
Recently launched by the non-profit Multiple Sclerosis Foundation (MSF), MSFocusRadio.org is the first online radio station for the…
Lipoatrophy Occurrence for MS Patients Higher than Originally Thought
The risk of developing lipoatrophy for multiple sclerosis (MS) patients administrated with glatiramer acetate is greater than 60 percent,…